Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Exchange Rate Effect (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Exchange Rate Effect for 15 consecutive years, with $100000.0 as the latest value for Q4 2025.

  • Quarterly Exchange Rate Effect rose 114.29% to $100000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $800000.0 through Dec 2025, up 180.0% year-over-year, with the annual reading at $800000.0 for FY2025, 180.0% up from the prior year.
  • Exchange Rate Effect for Q4 2025 was $100000.0 at Myriad Genetics, down from $600000.0 in the prior quarter.
  • The five-year high for Exchange Rate Effect was $1.2 million in Q3 2024, with the low at -$800000.0 in Q1 2024.
  • Average Exchange Rate Effect over 5 years is -$42105.3, with a median of $100000.0 recorded in 2021.
  • The sharpest move saw Exchange Rate Effect surged 600.0% in 2022, then plummeted 500.0% in 2024.
  • Over 5 years, Exchange Rate Effect stood at $100000.0 in 2021, then soared by 600.0% to $700000.0 in 2022, then changed by 0.0% to $700000.0 in 2023, then plummeted by 200.0% to -$700000.0 in 2024, then soared by 114.29% to $100000.0 in 2025.
  • According to Business Quant data, Exchange Rate Effect over the past three periods came in at $100000.0, $600000.0, and $100000.0 for Q4 2025, Q2 2025, and Q1 2025 respectively.